No Picture
News

IDEAYA Biosciences Reports End-of-Phase 1 Meeting with FDA for IDE196 Confirms Acceptability of Single-Arm Trial Design for Potential Phase 2 Registration-Enabling Study in Metastatic Uveal Melanoma

– FDA feedback from End-of-Phase 1 meeting indicates IDEAYA’s proposed single-arm Phase 2 clinical trial may be adequate to support an NDA seeking Accelerated Approval for IDE196 monotherapy in metastatic uveal melanoma (MUM)- Phase 2 dose selection a… […]

No Picture
News

Vik Bajaj unveils Foresite’s new incubator, looking to hatch future giants crossing tech and healthcare

When it comes to harnessing data for healthcare and the life sciences, a rich infrastructure of expansive data collected and measured with the right tools are essential to uncover new insights and advance new products. And to build that, you need acces… […]

No Picture
News

New Data: Foreign Reference Pricing Proposal in H.R. 3 Would Slash Life-Saving R&D and Lead to Destruction of California’s Life Sciences Sector

SAN FRANCISCO & SACRAMENTO, Calif. & SAN DIEGO & WASHINGTON–(BUSINESS WIRE)– #Biomedical–New Data: Foreign Reference Pricing Proposal in H.R. 3 Would Slash Life-Saving R&D and Lead to Destruction of California?s Life Sciences Sector […]

No Picture
News

Rallybio Expands Leadership Team and Strengthens Drug Acquisition Capabilities

FARMINGTON, Conn.–(BUSINESS WIRE)– #Rallybio–Rallybio LLC, a development-stage biotechnology company, today announced that it has further expanded its drug acquisition and development capabilities with the addition of Amanda Hayward, PhD and Lisa Si… […]

No Picture
News

Rallybio Expands Leadership Team and Strengthens Drug Acquisition Capabilities

FARMINGTON, Conn.–(BUSINESS WIRE)– #Rallybio–Rallybio LLC, a development-stage biotechnology company, today announced that it has further expanded its drug acquisition and development capabilities with the addition of Amanda Hayward, PhD and Lisa Si… […]

No Picture
News

Vivek Ramaswamy trades top execs and adds stealthy vant to $3B sale, while his new partner tosses Myovant $350M

Roivant chief Vivek Ramaswamy is picking up his $3 billion check from Sumitomo Dainippon in exchange for his stake in 5 of his startup vants ? along with an option on 6 more as well as an operations team to oversee their work. And the Japanese pharma i… […]

No Picture
News

Pliant Therapeutics to Present Preclinical Data in Primary Sclerosing Cholangitis at The Liver Meeting 2019

SOUTH SAN FRANCISCO, Calif., Oct. 31, 2019 /PRNewswire/ — Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis, today announced that company scien… […]